1 / 23

Panel 5: Current HIV Vaccine Research Clinical Research

Panel 5: Current HIV Vaccine Research Clinical Research. James Kublin, MD, MPH Executive Director, HVTN Journalist-2-Journalist Program Bangkok, Thailand September 12 th , 2011. Potential Impact of a Vaccine. Google : health affairs stover

durin
Télécharger la présentation

Panel 5: Current HIV Vaccine Research Clinical Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Panel 5: Current HIV Vaccine ResearchClinical Research James Kublin, MD, MPH Executive Director, HVTN Journalist-2-Journalist Program Bangkok, Thailand September 12th, 2011

  2. Potential Impact of a Vaccine Google: health affairs stover The Impact Of An AIDS Vaccine In Developing Countries: A New Model And Initial Results John Stover, Lori Bollinger, Robert Hecht, Clara Williams and Eva Roca Health Affairs 26(4):1147-1158 (2007) Even a vaccine with low efficacy and limited coverage can impact the epidemic and play a role in preventing future infections

  3. Potential Impact of a Vaccine • A general vaccination strategy in South Africa • between 2020 and 2030 • 60% of the population, • prevents 3.0M infections • 36% of expected infections • requiring only 39 vaccinations/infection averted. • Treatment for HIV in RSA • ~$930 (R6500) • second line therapy ~$1,716 (R12,000); • third line therapy ~$5,148 (R36,000).  • Treatment costs over 10 years = +$27,900,000,000 The potential impact of a moderately effective HIV vaccine with rapidly waning protection in South Africa and Thailand. Andersson KM, Stover J. Vaccine. 2011 Aug 18;29(36):6092-9. Epub 2011 Jun 22.

  4. HVTN Portfolio Outline • Fundamental Vaccinology and Innate Immunity • Memory and Mucosal Immunity • NHP – Clinical – Early Stage Investigator Scholar Awards • First in humans and novel combinations and adjuvants • Head-to-Head Comparisons • Later Phase Trials - Efficacy • Cohort Development • Studies of Infected Participants

  5. Med Ad5 Titer Low Ad5 Titer Med Ad5 Titer Clinical Research Achievements • Clinical Research • Laboratory • Analytic/Design *p<10-6, 1 way ANOVA Down-regulated Up-regulated

  6. Timeline of HIV vaccine efficacy trials Corey L et al. Sci Transl Med 2011;3:79ps13-79ps13

  7. HVTN 078 Amendment

  8. HVTN 086 SAAVI/Novartis • To characterize and rank the vaccine regimens • Identify the best performing vaccine regimen based on HIV-specific neutralizing antibody responses following vaccination with Novartis subtype C gp140/MF59 vaccine • As a concurrent or sequential boost to SAAVI MVA-C prime • As a concurrent boost with SAAVI MVA-C after SAAVI DNA-C2 prime

  9. Adaptive designs accelerate vaccine development Corey L et al. Sci Transl Med 2011;3:79ps13-79ps13 Published by AAAS

  10. Trial Example Schema 2 vaccine regimens vs. a shared placebo group Examples of upcoming vaccines include ALVAC, NYVAC, DNAs, gp120, MVAs, Ad26, Ad35, immunoprophylaxis, etc. HIV negative subjects enrolled and tested for HIV infection 2-monthly for a maximum of 36 months

  11. Research Trial Duration for Each Vaccine Arm • Assumptions: • N = 2,150 / group • Annual sero-incidence in placebo • group = 3% • Annual rate of loss to follow-up = 5% • 18 mo enrollment period • Avg enrollment = 391 per mo halved during first 3 mo • Vaccination regimen completed at • 12 mo • VEhalved during first 6 mo • HIV testing bi-monthly • for up to 36 mo • Maximum of 134 HIV infections • for one vaccine regimen + placebo

  12. Objectives of the Design Primary objective: For each vaccine regimen, evaluate VE against infections diagnosed within 18 months of randomization [i.e., VE(0-18)] Secondary objectives: To evaluate durability of VE out to 36 months for each regimen showing reliable evidence for positive VE(0-18) To expeditiously and rigorously evaluate immune correlates of protection if any of the vaccine regimens show reliable evidence for positive VE(0-18), including sieve analysis To compare VE between the 2 vaccine regimens To evaluate vaccine effects on HIV-1 progression for 18 months post-diagnosis, including viral load, CD4+ T cell count, HAART, and AIDS endpoints Exploratory objectives: Several, including behavioral assessments with emphasis on PrEP use

  13. Research Trial Divided into 2 Stages A 2-stage design separately for each vaccine regimen: Stage 1 evaluates VE(0-18) Stage 2 evaluates longer-term VE(t), and occurs if, and only if, the trial provides reliable evidence for VE(0-18) > 0% Premise: The vaccine will not confer greater efficacy for exposures more distal from the immunization series

  14. Application of Monitoring Plan to RV144 Proposed Design Est. VE(0-18), 95% CI, 2-sided p-value: 49%, 32% to 82%, p=0.006.

  15. Immune Correlates Analysis Goal: Expeditiously evaluate priority immunological parameters as “immune correlates of protection” For each vaccine not weeded out for non-efficacy ~6months before the projected final analysis of VE(0-18), begin measurements on vaccine arm infected cases to date and frequency matched uninfected vaccine recipients Such vaccines have VE(0-18) estimates at least 25% and merit initiation of the immune correlates analysis Design the trial to offer any vaccine showing efficacy on VE(0-18) to all placebo recipients at study close-out (36 months) Measure vaccine-induced immune responses for the vaccinated placebo recipients, which is useful for evaluating immune surrogates

  16. Filling in the Immunological Space

  17. Cost Drivers for Phase 2b Studies • Cost drivers • Sample size – determined by: • vaccine efficacy • duration of follow-up • incidence • Number of injections • Frequency of visits • PBMC time points • Number of clinical sites • Site and Lab Capacity • Square feet • Footsteps • Hands and hoods - PBMCs

  18. Sample sizes (per arm) for testing VE=40% vs. VE=0% for range of infection rates* * Testing done as in Gilbert et al.’s phase 2b design manuscript, using all of their assumptions except modifying the placebo incidence

  19. HVTN/CHAVI NHP Early Stage Investigator Scholar Award Funding Pilot Studies to Advance Non-Human Primate Models in Support of HIV Vaccines Clinical Research

  20. 2011 Scholars – Cohort 3 Keith Reeves Carolina Herrera Afam Okoye Wendy Yeh Lu-Ann Pozzi Shaunna Shen New England Primate Research Center St. George's, University of London Oregon Health and Science University Beth Israel Deaconess Medical Center New England Primate Research Center Duke University

  21. Thanks • Peter Gilbert • Larry Corey • Julie McElrath • Glenda Gray • Georgia Tomaras • Jerome Kim

  22. HVTN.org/Science/HVTNews • Informs readers about the science of the HVTN, the management of the Network’s many multilateral collaborations, and our outstanding clinical sites. • Current issue includes articles on Epitope Mapping, Adaptive Trial Design, and Exploring Barriers and Facilitators in the Recruitment of Transgender Women.

More Related